| Revenue growth | FY26 grew 4.8% YoY; MedTech segment grew 46% YoY. |
|---|---|
| Margins | Consolidated EBITDA margin 14.5% in FY26; MedTech achieved positive EBITDA. |
| Demand visibility | Strong comeback in international patient volumes in April-May 2026. |
| Management confidence | High confidence in short-term EBITDA breakeven for Shalby International. |
Growth
FY26 Consolidated Revenue up 4.8% to ₹1,168.2cr; Q4 PAT ₹18.5cr vs ₹12.2cr loss YoY.
Outlook
Guided minimum 15% CAGR for hospitals; MedTech revenue target ₹600-700cr by 2030 with >15% EBITDA.
Risks
Geopolitical conflict in Middle East impacting international patient inflows at Gurugram; doctor attrition during H1 FY26.
Earnings Call filed with NSE, NSE: SHALBY. Summary written with AI assistance from the document.
Shalby Limited: key numbers
- Share price
- ₹135.00
- Market cap
- ₹1,458 Cr
- Revenue (annual)
- ₹1,141 Cr
- Net profit (annual)
- ₹37.39 Cr
- P/E (TTM)
- 37.1×Sector 53.1×
- Promoter holding
- 74.33%+0.00% QoQ
- FII holding
- 4.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shalby Limited
All →Shalby Management Change
Shareholders at the AGM did not approve the appointment of Mr. Shanay Vikram Shah as Director, resulting in his cessation from the Board effective September 10, 2026.
Shalby Annual General Meeting
Shalby Limited held its 22nd Annual General Meeting on September 10, 2026. The meeting covered adoption of financial statements and appointment of a whole-time director.
Shalby Other Announcement
Shalby Limited has issued a letter to shareholders providing the web-link for the Annual Report for FY 2025-26. The 22nd Annual General Meeting is scheduled for September 10, 2026.
Shalby Business Update
Shalby Limited filed its Business Responsibility & Sustainability Report (BRSR) for FY 2025-26 as mandated by SEBI LODR regulations.
Shalby Annual General Meeting
Shalby Ltd announced its 22nd Annual General Meeting scheduled for September 10, 2026, and filed its Annual Report for FY 2025-26.
Shalby Earnings Call Transcript: Key Takeaways
Shalby reported a modest 11.6% revenue growth with its MetLife business reaching EBITDA break-even, but hospital margins remain under pressure due to new doctor recruitments.
- Call
- Guides 20% growth